203 related articles for article (PubMed ID: 9170427)
1. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas.
Söderlund V; Jonsson C; Bauer HC; Brosjö O; Jacobsson H
J Nucl Med; 1997 May; 38(5):682-6. PubMed ID: 9170427
[TBL] [Abstract][Full Text] [Related]
2. The role of 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpression in patients with musculoskeletal sarcomas: comparison with therapy response.
Burak Z; Ersoy O; Moretti JL; Erinç R; Ozcan Z; Dirlik A; Sabah D; Basdemir G
Eur J Nucl Med; 2001 Sep; 28(9):1341-50. PubMed ID: 11585293
[TBL] [Abstract][Full Text] [Related]
3. Comparison of technetium-99m-MIBI, technetium-99m-tetrofosmin, ultrasound and MRI for localization of abnormal parathyroid glands.
Ishibashi M; Nishida H; Hiromatsu Y; Kojima K; Tabuchi E; Hayabuchi N
J Nucl Med; 1998 Feb; 39(2):320-4. PubMed ID: 9476944
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluorine-18-FDG PET and technetium-99m-MIBI SPECT in evaluation of musculoskeletal sarcomas.
Garcia R; Kim EE; Wong FC; Korkmaz M; Wong WH; Yang DJ; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1476-9. PubMed ID: 8790197
[TBL] [Abstract][Full Text] [Related]
5. Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells.
Arbab AS; Koizumi K; Toyama K; Arai T; Araki T
J Nucl Med; 1998 Feb; 39(2):266-71. PubMed ID: 9476934
[TBL] [Abstract][Full Text] [Related]
6. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease.
Münch G; Neverve J; Matsunari I; Schröter G; Schwaiger M
J Nucl Med; 1997 Mar; 38(3):428-32. PubMed ID: 9074532
[TBL] [Abstract][Full Text] [Related]
7. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines.
Arbab AS; Koizumi K; Toyama K; Araki T
J Nucl Med; 1996 Sep; 37(9):1551-6. PubMed ID: 8790217
[TBL] [Abstract][Full Text] [Related]
8. Comparative 99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-furifosmin uptake in human soft tissue sarcoma cell lines.
Rodriques M; Chehne F; Kalinowska W; Zielinski C; Sinzinger H
Eur J Nucl Med; 2000 Dec; 27(12):1839-43. PubMed ID: 11189948
[TBL] [Abstract][Full Text] [Related]
9. A head-to-head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions.
Obwegeser R; Berghammer P; Rodrigues M; Granegger S; Hohlagschwandtner M; Kucera H; Singer C; Berger A; Kubista E; Sinzinger H
Eur J Nucl Med; 1999 Dec; 26(12):1553-9. PubMed ID: 10638406
[TBL] [Abstract][Full Text] [Related]
10. Effect of asiaticoside on 99mTc-tetrofosmin and 99mTc-sestamibi uptake in MCF-7 cells.
Al-Saeedi FJ; Bitar M; Pariyani S
J Nucl Med Technol; 2011 Dec; 39(4):279-83. PubMed ID: 22080437
[TBL] [Abstract][Full Text] [Related]
11. Technetium-99m-tetrofosmin scintigraphy in patients with metastatic soft tissue sarcoma.
Karanikas G; Köstler WJ; Becherer A; Wiesner K; Dudczak R; Krainer M; Kletter K
Oncol Rep; 2002; 9(5):1009-13. PubMed ID: 12168065
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities.
Moustafa H; Riad R; Omar W; Zaher A; Ebied E
Q J Nucl Med; 2003 Mar; 47(1):51-7. PubMed ID: 12714955
[TBL] [Abstract][Full Text] [Related]
13. Correlation of 99mTc-sestamibi uptake with blood-pool and osseous phase 99mTc-MDP uptake in malignant bone and soft-tissue tumours.
Ozcan Z; Burak Z; Erinç R; Dirlik A; Başdemir G; Sabah D; Ozkiliç H
Nucl Med Commun; 2001 Jun; 22(6):679-83. PubMed ID: 11403180
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-tetrofosmin scintigraphy in musculoskeletal tumours: the relationship between P-glycoprotein expression and tetrofosmin uptake in malignant lesions.
Yapar Z; Kibar M; Ozbarlas S; Yapar AF; Uguz A; Zorludemir S; Herdem M
Nucl Med Commun; 2002 Oct; 23(10):991-1000. PubMed ID: 12352598
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of histopathological tumor response to preoperative chemotherapy by Tc-99m MIBI imaging in bone and soft tissue sarcomas.
Taki J; Inaki A; Wakabayashi H; Sumiya H; Tsuchiya H; Zen Y; Kinuya S
Clin Nucl Med; 2010 Mar; 35(3):154-9. PubMed ID: 20173444
[TBL] [Abstract][Full Text] [Related]
16. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies.
Aigner RM; Fueger GF; Nicoletti R
Eur J Nucl Med; 1996 Jun; 23(6):693-6. PubMed ID: 8662105
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-MIBI scintigraphy in musculoskeletal tumors.
Pinkas L; Robinson D; Halperin N; Mindlin L; Cohenpour M; Baumer M; Home T
J Nucl Med; 2001 Jan; 42(1):33-7. PubMed ID: 11197977
[TBL] [Abstract][Full Text] [Related]
19. Uptake of 99mTc-MIBI and 99mTc-tetrofosmin into malignant versus nonmalignant breast cell lines.
Rodrigues M; Chehne F; Kalinowska W; Berghammer P; Zielinski C; Sinzinger H
J Nucl Med; 2000 Sep; 41(9):1495-9. PubMed ID: 10994728
[TBL] [Abstract][Full Text] [Related]
20. 99mTc isonitrils biophysical aspects in pulmonary tuberculosis. Part I. In vivo evaluation of 99mTc MIBI and 99mTc Tetrofosmin biophysical localization mechanisms.
Stefanescu C; Rusu V; Boişteanu D; Azoicai D; Costin M; Oleniuc D; Hurjui M; Sattish P
Rev Med Chir Soc Med Nat Iasi; 2006; 110(4):944-9. PubMed ID: 17438905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
